The safety profile of sublingual peptides depends primarily on the specific peptide being administered rather than the delivery route
enthusiasm dramatically outpaces science FDA Category 2 classifications for peptides like Semax reflect absence of FDA-standard evidence, not documented harmsRussian clinical experience suggests reasonable safety, but long-term effects by Western standards remain uncharacterized Established interventionsexercise, Mediterranean diet, sleep optimization, cardiovascular risk management, cognitive engagementhave far more consistent evidence than any peptide for dementia risk reduction For Research Prioritization Compounds meriting continued investigation: GLP-1 Agonists: Prevention trials in preclinical/presymptomatic populations, testing compounds with better brain penetration (dulaglutide, lixisenatide) SS-31/Elamipretide: Cognitive outcomes in mitochondrial disease populations, potential expansion to brain aging indications P21: Phase I human trials to establish safety, pharmacokinetics, and proof-of-mechanism for CNTF-pathway neurogenesis Klotho: Watch for Phase 1 results from Jocasta Neuroscience (expected 2027-2028)
E., Kamiya, T., Kawada, Y., Renshaw, P
2018 RCT is well-designed and positive - and it's not the final word
Cabe destacar que por medio de la alimentacin nunca se consigue consumir la dosificacin necesaria para promover la quema de grasa, por lo que la suplementacin es la mejor opcin
150 MathieuC.PappuR
